1 Chang MH., "The significance of spontaneous hepatitis B e antigen seroconversion in childhood : with special emphasis on the clearance of hepatitis B e antigen before 3 years of age" 22 : 1387-1392, 1995
2 de Franchis R., "The natural history of asymptomatic hepatitis B surface antigen carriers" 118 : 191-194, 1993
3 Vierling JM., "The immunology of hepatitis B" 11 : 727-759, 2007
4 Liu HL., "The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy" 20 : 645-649, 2013
5 Chen XQ., "The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy" 29 : 1237-1241, 2012
6 Kishida D., "Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis" 21 : 215-218, 2011
7 Cheng AL., "Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV)reactivation in HBV-carriers with lymphoma" 37 : 1320-1328, 2003
8 Gupta S., "Spontaneous reactivation in chronic hepatitis B : patterns and natural history" 12 : 562-568, 1990
9 Martinot-Peignoux M., "Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers" 36 : 543-546, 2002
10 McMahon BJ., "Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus" 135 : 759-768, 2001
1 Chang MH., "The significance of spontaneous hepatitis B e antigen seroconversion in childhood : with special emphasis on the clearance of hepatitis B e antigen before 3 years of age" 22 : 1387-1392, 1995
2 de Franchis R., "The natural history of asymptomatic hepatitis B surface antigen carriers" 118 : 191-194, 1993
3 Vierling JM., "The immunology of hepatitis B" 11 : 727-759, 2007
4 Liu HL., "The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy" 20 : 645-649, 2013
5 Chen XQ., "The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy" 29 : 1237-1241, 2012
6 Kishida D., "Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis" 21 : 215-218, 2011
7 Cheng AL., "Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV)reactivation in HBV-carriers with lymphoma" 37 : 1320-1328, 2003
8 Gupta S., "Spontaneous reactivation in chronic hepatitis B : patterns and natural history" 12 : 562-568, 1990
9 Martinot-Peignoux M., "Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers" 36 : 543-546, 2002
10 McMahon BJ., "Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus" 135 : 759-768, 2001
11 Kim PS., "Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B" 64 : 1265-1268, 2012
12 Dong HJ., "Risk of hepatitis B virus(HBV)reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy : a meta-analysis" 57 : 209-214, 2013
13 Nard FD., "Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment : Extending perspective from old to newer drugs" 7 : 344-361, 2015
14 Ghrénassia E., "Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis" 79 : 100-101, 2012
15 Germanidis G., "Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept" 56 : 1420-1421, 2012
16 Nakamura J, "Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs" 2014
17 Chung SJ., "Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy" 36 : 2416-2420, 2009
18 Pyrpasopoulou A., "Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis" 31 : 403-404, 2011
19 Chen YC., "Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection" 123 : 1084-1089, 2002
20 Rossi G., "Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy" 115 : 58-62, 2001
21 Sim JG., "Prevalence and its changes of hepatitis b viral markers from 1988 to 1993 in Korean children" 38 : 1535-1539, 1995
22 Lau GK., "Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation" 36 : 702-709, 2002
23 Yoo BC., "Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea" 38 : 98-103, 2003
24 Kim YJ., "Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases" 37 : 346-350, 2010
25 Zacharakis GH., "Natural history of chronic HBV infection : a cohort study with up to 12 years follow-up in North Greece(part of the Interreg I-II/EC-project)" 77 : 173-179, 2005
26 Hui CK., "Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase" 46 : 395-401, 2007
27 Hwang JP., "Management of patients with hepatitis B who require immunosuppressive therapy" 11 : 209-219, 2014
28 Hoofnagle JH., "Management of hepatitis B : summary of a clinical research workshop" 45 : 1056-1075, 2007
29 Mitroulis I., "Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection" 72 : 308-310, 2013
30 Yeo W., "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy" 22 : 927-934, 2004
31 Ministry of Health & Welfare, "Korea health statistics 2011:Korea national health and nutrition examination survey (KNHANESV-2)"
32 Lan JL., "Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy" 70 : 1719-1725, 2011
33 Droz N., "Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases" 65 : 1504-1514, 2013
34 Croagh CM., "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B" 30 : 1115-1122, 2010
35 Tran TT., "Immune tolerant hepatitis B : a clinical dilemma" 7 : 511-516, 2011
36 Pérez-Alvarez R., "Hepatitis B virus(HBV)reactivation in patients receiving tumor necrosis factor(TNF)-targeted therapy : analysis of 257 cases" 90 : 359-371, 2011
37 Okamoto H., "Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen" 68 : 8102-8110, 1994
38 Jang JW., "Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy" 20 : 7675-7685, 2014
39 Yeo W., "Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab" 27 : 605-611, 2009
40 Lee YH., "Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs" 16 : 527-531, 2013
41 Kim SJ., "Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab : analysis from the Asia Lymphoma Study Group" 49 : 3486-3496, 2013
42 Gigi E., "Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab" 17 : 91-93, 2013
43 Hui CK., "Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy" 54 : 1597-1603, 2005
44 Saab S., "Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma : a decision analysis model" 46 : 1049-1056, 2007
45 Lau GK., "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy" 125 : 1742-1749, 2003
46 Yeo W., "Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy" 43 : 209-220, 2006
47 Yeo W., "Comprehensive analysis of risk factors associating with Hepatitis B virus(HBV)reactivation in cancer patients undergoing cytotoxic chemotherapy" 90 : 1306-1311, 2004
48 Li HR., "Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy" 18 : 877-883, 2011
49 Lok AS., "Chronic hepatitis B : update 2009" 50 : 661-662, 2009
50 Lok AS., "Chronic hepatitis B" 45 : 507-539, 2007
51 Hsu C., "Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection : a prospective study" 59 : 2092-2100, 2014
52 Lee PI., "Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children" 12 : 657-660, 1990
53 Tsai SL., "Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion" 89 : 87-96, 1992
54 Lok AS., "Acute exacerbations in Chinese patients with chronic hepatitis B virus(HBV)infection. Incidence, predisposing factors and etiology" 10 : 29-34, 1990
55 Hsu C., "A revisit of prophylactic lamivudine for chemotherapyassociated hepatitis B reactivation in non-Hodgkin's lymphoma : a randomized trial" 47 : 844-853, 2008
56 Ahn YO., "A review study on descriptive epidemiology of HBs antigen positivity in Korea" 4 : 35-45, 1982
57 Lok AS., "A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children" 8 : 1130-1133, 1988